FINWIRES · TerminalLIVE
FINWIRES

イベルドローラ社の第1四半期の発電量は設備容量の増加により上昇

By

-- スペインの電力会社イベルドローラは水曜日、第1四半期の発電量が前年同期比1.6%増加したと発表した。これは設備容量が3.8%増加したことが要因となっている。 3月31日までの四半期の純発電量は36.106テラワット時(TWh)で、うち25.62TWhは再生可能エネルギー源によるものだった。 洋上風力発電量は42%増の2.639TWh、太陽光発電量は1.7%増の1.703TWhとなった。一方、陸上風力発電量は2.7%減の11.775TWh、水力発電量は1.1%減の9.366TWhとなった。 ガスタービン複合サイクル発電所の発電量は42.5%増の3.453TWh、原子力発電量は12.7%減の5.464TWhとなった。 同時に、イベルドローラの設備容量は前年比3.8%増の58.877ギガワットに拡大しました。これは主に、エネルギー貯蔵、太陽光発電、風力発電の設備容量の増加によるものです。 電力とガスの供給量は、それぞれ前年比10.6%増の27.132テラワット時、2.4%増の15.196テラワット時となりました。 送配電事業では、供給拠点数が8.7%増の3,710万ヶ所となったことが牽引役となり、配電量は9.7%増の68.645テラワット時となりました。英国が成長を牽引し、配電量は72.6%増の14.687テラワット時、供給拠点数は69.4%増の610万ヶ所となりました。 一方、米国におけるガスの配電量は5.5%減の25.582テラワット時となり、供給拠点数は0.7%減の100万ヶ所となりました。

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS